Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFNα:: results from the Primoferon A (ANRS 086) Study

被引：46

作者：

Emilie, D ^{[1
]}

Burgard, M

Lascoux-Combe, C

Laughlin, M

Krzysiek, R

Pignon, C

Rudent, A

Molina, JM

Livrozet, JM

Souala, F

Chene, G

Grangeot-Keros, L

Galanaud, P

Sereni, D

Rouzioux, C

机构：

[1] Inst Paris Sud Cytokines, Hop Antoine Beclere, Serv Med Interne & Immunol Clin, Clamart, France

[2] Inst Paris Sud Cytokines, Hop Antoine Beclere, Serv Microbiol Immunol, Clamart, France

[3] CHU Necker Enfants Malad, Virol Lab, Paris, France

[4] Hop St Louis, Serv Med Interne, Paris, France

[5] Hop St Louis, Serv Malad Infect, Paris, France

[6] Schering Plough Res Inst, Kenilworth, NJ USA

[7] Hop Edouard Herriot, Serv Med Transplantat & Immunol, Lyon, France

[8] Hop Pontchaillou, Serv Malad Infect, Rennes, France

[9] INSERM, U330, Bordeaux, France

来源：

AIDS | 2001年 / 15卷 / 11期

关键词：

D O I：

10.1097/00002030-200107270-00014

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

IFN alpha has both antiviral and immunostimulating properties. The ANRS086 Primoferon A Study evaluated, in 12 patients with primary HIV infection the tolerance and efficacy of an early and transient administration of pegylated IFN alpha, in addition to highly active antiretroviral therapy. Tolerance was good, and this regimen allowed the early control of HIV replication and rapid decay of the viral reservoir. These results support the initiation of comparative studies with pegylated IFN alpha in primary HIV infection.

引用

页码：1435 / 1437

页数：3

共 25 条

[11] INTERFERONS IN HIV AND RELATED DISEASES [J].

LANE, HC .

AIDS, 1994, 8 :S19-S23

[12] Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection [J].

Lillo, FB ;

Ciuffreda, D ;

Veglia, F ;

Capiluppi, B ;

Mastrorilli, E ;

Vergani, B ;

Tambussi, G ;

Lazzarin, A .

AIDS, 1999, 13 (07) :791-796

[13] Viral dynamics of acute HIV-1 infection [J].

Little, SJ ;

McLean, AR ;

Spina, CA ;

Richman, DD ;

Havlir, DV .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (06) :841-850

[14] Type 1 IFN maintains the survival of anergic CD4+ T cells [J].

Lombardi, G ;

Dunne, PJ ;

Scheel-Toellner, D ;

Sanyal, T ;

Pilling, D ;

Taams, LS ;

Life, P ;

Lord, JM ;

Salmon, M ;

Akbar, AN .

JOURNAL OF IMMUNOLOGY, 2000, 165 (07) :3782-3789

[15] Type I interferons keep activated T cells alive [J].

Marrack, P ;

Kappler, J ;

Mitchell, T .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (03) :521-529

[16] FUNCTIONAL-ROLE OF TYPE-I AND TYPE-II INTERFERONS IN ANTIVIRAL DEFENSE [J].

MULLER, U ;

STEINHOFF, U ;

REIS, LFL ;

HEMMI, S ;

PAVLOVIC, J ;

ZINKERNAGEL, RM ;

AGUET, M .

SCIENCE, 1994, 264 (5167) :1918-1921

[17] Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy [J].

Ngo-Giang-Huong, N ;

Deveau, C ;

Da Silva, I ;

Pellegrin, I ;

Venet, A ;

Harzic, M ;

Sinet, M ;

Delfraissy, JF ;

Meyer, L ;

Goujard, C ;

Rouzioux, C .

AIDS, 2001, 15 (06) :665-673

[18]

Pfeffer LM, 1998, CANCER RES, V58, P2489

[19] INHIBITION BY INTERFERON OF HERPES-SIMPLEX VIRUS TYPE-1-ACTIVATED TRANSCRIPTION OF TAT-DEFECTIVE PROVIRUS [J].

POPIK, W ;

PITHA, PM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (21) :9573-9577

[20] Selective expression of an interleukin-12 receptor component by human T helper 1 cells [J].

Rogge, L ;

BarberisMaino, L ;

Biffi, M ;

Passini, N ;

Presky, DH ;

Gubler, U ;

Sinigaglia, F .

JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (05) :825-831

← 1 2 3 →